Compare BridgeBio Pharma Inc (BBIO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs BlackRock TCP Capital Corp — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while BlackRock TCP Capital Corp trades at $3.18 (market cap $265.55M). The key difference: BridgeBio Pharma Inc is far larger — about 62× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.54% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TCPC | |
|---|---|---|
Market Cap | $16.46B | $265.55M |
Sector | Health | Financials |
52-Week High | $90.17 | $7.84 |
52-Week Low | $44.81 | $3.14 |
Enterprise Value | $18.02B | — |
Dividend Yield | — | 26.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TCPC trades at $3.15, down 3.37% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025 despite a 112% net income margin, driven by negative revenue. Analyst consensus shows mixed sentiment with 31% buy ratings, while recent news includes a Zacks upgrade and upcoming Q2 earnings on August 6, 2026.
The outlook remains challenging with persistent negative revenue and profitability issues. Investment opportunities include the low P/B ratio of 0.47 and dividend yield, but risks include ongoing losses, shareholder litigation, and bearish technical indicators. The stock faces significant fundamental headwinds despite some analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
